Vertex Pharmaceuticals annual operating income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vertex Pharmaceuticals Operating Income Growth & History (VRTX)
Vertex Pharmaceuticals's operating income was $4.17B for fiscal 2025.
View full Vertex Pharmaceuticals company overviewVertex Pharmaceuticals annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.17B | $4.41B | — |
| 2024 | 2024-12-31 | −$232.9M | −$4.06B | — |
| 2023 | 2023-12-31 | $3.83B | −$475.4M | −11.04% |
| 2022 | 2022-12-31 | $4.31B | $1.53B | +54.83% |
| 2021 | 2021-12-31 | $2.78B | −$74.2M | −2.60% |
| 2020 | 2020-12-31 | $2.86B | $1.66B | +138.52% |
| 2019 | 2019-12-31 | $1.20B | $562.4M | +88.54% |
| 2018 | 2018-12-31 | $635.1M | $511.9M | +415.36% |
| 2017 | 2017-12-31 | $123.2M | $113.3M | +1140.37% |
| 2016 | 2016-12-31 | $9.9M | $476.8M | — |
| 2015 | 2015-12-31 | −$466.9M | $225.5M | — |
| 2014 | 2014-12-31 | −$692.4M | −$82.4M | — |
| 2013 | 2013-12-31 | −$610.0M | −$656.7M | — |
| 2012 | 2012-12-31 | $46.7M | −$67.1M | −58.95% |
| 2011 | 2011-12-31 | $113.8M | $809.9M | — |
| 2010 | 2010-12-31 | −$696.1M | −$82.1M | — |
| 2009 | 2009-12-31 | −$614.0M | −$151.3M | — |
| 2008 | 2008-12-31 | −$462.7M | — | — |
Vertex Pharmaceuticals quarterly operating income
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.25B | $95.8M | +8.32% |
| Q1 2026 | 2026-03-31 | $1.14B | $508.0M | +80.62% |
| Q4 2025 | 2025-12-31 | $1.21B | $179.9M | +17.53% |
| Q3 2025 | 2025-09-30 | $1.19B | $69.9M | +6.26% |
| Q2 2025 | 2025-06-30 | $1.15B | $4.67B | — |
| Q1 2025 | 2025-03-31 | $630.1M | −$509.4M | −44.70% |
| Q4 2024 | 2024-12-31 | $1.03B | $37.5M | +3.79% |
| Q3 2024 | 2024-09-30 | $1.12B | $78.2M | +7.53% |
| Q2 2024 | 2024-06-30 | −$3.51B | −$4.54B | — |
| Q1 2024 | 2024-03-31 | $1.14B | $360.5M | +46.28% |
| Q4 2023 | 2023-12-31 | $988.5M | −$45.0M | −4.35% |
| Q3 2023 | 2023-09-30 | $1.04B | −$88.6M | −7.86% |
| Q2 2023 | 2023-06-30 | $1.03B | −$79.9M | −7.22% |
| Q1 2023 | 2023-03-31 | $779.0M | −$261.9M | −25.16% |
| Q4 2022 | 2022-12-31 | $1.03B | $155.8M | +17.75% |
| Q3 2022 | 2022-09-30 | $1.13B | $72.2M | +6.85% |
| Q2 2022 | 2022-06-30 | $1.11B | $1.14B | — |
| Q1 2022 | 2022-03-31 | $1.04B | $153.1M | +17.24% |
| Q4 2021 | 2021-12-31 | $877.7M | $131.9M | +17.69% |
| Q3 2021 | 2021-09-30 | $1.05B | $382.3M | +56.86% |
| Q2 2021 | 2021-06-30 | −$37.9M | −$755.9M | — |
| Q1 2021 | 2021-03-31 | $887.8M | $167.6M | +23.27% |
| Q4 2020 | 2020-12-31 | $745.8M | $194.3M | +35.24% |
| Q3 2020 | 2020-09-30 | $672.2M | $572.9M | +576.75% |
| Q2 2020 | 2020-06-30 | $718.0M | $448.1M | +165.98% |
| Q1 2020 | 2020-03-31 | $720.2M | $443.4M | +160.19% |
| Q4 2019 | 2019-12-31 | $551.5M | $423.7M | +331.77% |
| Q3 2019 | 2019-09-30 | $99.3M | −$106.3M | −51.70% |
| Q2 2019 | 2019-06-30 | $270.0M | $97.1M | +56.16% |
| Q1 2019 | 2019-03-31 | $276.8M | $147.9M | +114.74% |
| Q4 2018 | 2018-12-31 | $127.7M | $2.0M | +1.58% |
| Q3 2018 | 2018-09-30 | $205.6M | $531.7M | — |
| Q2 2018 | 2018-06-30 | $172.9M | $120.2M | +228.00% |
| Q1 2018 | 2018-03-31 | $128.9M | −$141.9M | −52.41% |
| Q4 2017 | 2017-12-31 | $125.7M | $86.1M | +217.20% |
| Q3 2017 | 2017-09-30 | −$326.0M | −$307.3M | — |
| Q2 2017 | 2017-06-30 | $52.7M | $49.4M | +1471.94% |
| Q1 2017 | 2017-03-31 | $270.8M | $285.2M | — |
| Q4 2016 | 2016-12-31 | $39.6M | $93.3M | — |
| Q3 2016 | 2016-09-30 | −$18.7M | $51.3M | — |
| Q2 2016 | 2016-06-30 | $3.4M | $174.5M | — |
| Q1 2016 | 2016-03-31 | −$14.3M | $157.7M | — |
| Q4 2015 | 2015-12-31 | −$53.7M | $99.9M | — |
| Q3 2015 | 2015-09-30 | −$70.0M | $72.2M | — |
| Q2 2015 | 2015-06-30 | −$171.2M | $9.4M | — |
| Q1 2015 | 2015-03-31 | −$172.0M | $44.1M | — |
| Q4 2014 | 2014-12-31 | −$153.6M | −$143.3M | — |
| Q3 2014 | 2014-09-30 | −$142.2M | −$18.6M | — |
| Q2 2014 | 2014-06-30 | −$180.5M | −$133.5M | — |
| Q1 2014 | 2014-03-31 | −$216.0M | $213.1M | — |
| Q4 2013 | 2013-12-31 | −$10.3M | $67.2M | — |
| Q3 2013 | 2013-09-30 | −$123.6M | −$122.5M | — |
| Q2 2013 | 2013-06-30 | −$47.0M | −$36.3M | — |
| Q1 2013 | 2013-03-31 | −$429.1M | −$520.8M | — |
| Q4 2012 | 2012-12-31 | −$77.5M | −$301.4M | — |
| Q3 2012 | 2012-09-30 | −$1.1M | −$216.8M | — |
| Q2 2012 | 2012-06-30 | −$10.8M | $155.1M | — |
| Q1 2012 | 2012-03-31 | $91.6M | $251.5M | — |
| Q4 2011 | 2011-12-31 | $223.9M | $390.5M | — |
| Q3 2011 | 2011-09-30 | $215.7M | $415.3M | — |
| Q2 2011 | 2011-06-30 | −$165.9M | $3.7M | — |
| Q1 2011 | 2011-03-31 | −$159.9M | $383,000 | — |
| Q4 2010 | 2010-12-31 | −$166.6M | −$19.9M | — |
| Q3 2010 | 2010-09-30 | −$199.6M | −$51.4M | — |
| Q2 2010 | 2010-06-30 | −$169.6M | −$12.4M | — |
| Q1 2010 | 2010-03-31 | −$160.3M | $1.6M | — |
| Q4 2009 | 2009-12-31 | −$146.7M | — | — |
| Q3 2009 | 2009-09-30 | −$148.2M | — | — |
| Q2 2009 | 2009-06-30 | −$157.2M | — | — |
| Q1 2009 | 2009-03-31 | −$161.9M | — | — |
Vertex Pharmaceuticals operating income trends
Over the last five fiscal years, Vertex Pharmaceuticals's operating income increased from $2.86B to $4.17B, a change of $1.32B. The latest reported quarter, Q2 2026, shows $1.25B.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vertex Pharmaceuticals source filings ↗Community posts
Vertex adds detailed kidney-response data and launches patient-experience trial
Vertex ($VRTX) released additional Phase 3 RAINIER findings for povetacicept in IgA nephropathy. At week 36, 42.2% of treated participants achieved a urine protein-to-creatinine ratio below 0.5 grams per gram, compared with 6.2% receiving p ...
